Retatrutide 15 mg Vial – Triple-Receptor Synthetic Peptide

Retatrutide is a synthetic, long-acting peptide designed as a triple agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This multi-receptor activation profile makes it a promising candidate for advanced research into metabolic disorders, obesity, and glucose regulation.

By engaging all three incretin and glucagon pathways, Retatrutide has demonstrated the potential to enhance insulin secretion, reduce appetite, improve lipid metabolism, and increase energy expenditure — making it a valuable tool for cutting-edge metabolic and endocrinology research

Retatrutide Peptide Explained 

• Type – Long-acting synthetic triple agonist peptide.
• Receptor targets – GLP-1, GIP, and glucagon receptors.
• Potential research effects – Enhances glucose-dependent insulin release, suppresses glucagon secretion, delays gastric emptying, promotes lipid oxidation, and supports weight regulation models.
• Form – Sterile, lyophilized powder.
• Molecular details – Engineered for extended half-life via strategic amino acid substitutions and fatty acid conjugation to albumin-binding sites.